Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46).

Thomas R De RidderJustine E CampbellCheryl Burke-SchwarzDavid CleggEmily L ElliotSamuel GellerWendy KozakStephen T PittengerJennifer B PruittJocelyn RiehlJulie WhiteMelissa L WiestChad M JohannesJohn MortonPamela D JonesPeter F SchmidtVictoria GordonPaul Reddell

Published in: Journal of veterinary internal medicine (2020)

Tigilanol tiglate is efficacious and well tolerated, providing a new option for the local treatment of MCTs in dogs.

Keyphrases

double blind
randomized controlled trial
clinical trial
open label
phase iii
phase ii
smoking cessation